Tilray Brands, Inc. (NASDAQ:TLRY) Receives Consensus Rating of “Hold” from Analysts

Shares of Tilray Brands, Inc. (NASDAQ:TLRY) have been given a consensus rating of “Hold” by the eight analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $11.50.

A number of research firms recently issued reports on TLRY. Roth Mkm upgraded shares of Tilray Brands from a “neutral” rating to a “buy” rating and set a $10.00 target price on the stock in a research note on Thursday, April 2nd. Wall Street Zen upgraded shares of Tilray Brands from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Weiss Ratings lowered shares of Tilray Brands from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 13th. Zacks Research upgraded shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 11th. Finally, TD Cowen lowered their target price on shares of Tilray Brands from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday, March 30th.

Insider Transactions at Tilray Brands

In related news, Director David G. Hopkinson sold 33,556 shares of the firm’s stock in a transaction on Tuesday, April 21st. The shares were sold at an average price of $6.94, for a total value of $232,878.64. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.84% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Oppenheimer & Co. Inc. acquired a new position in Tilray Brands in the 3rd quarter valued at $25,000. Y Intercept Hong Kong Ltd bought a new stake in Tilray Brands in the 3rd quarter valued at $30,000. HighPoint Advisor Group LLC bought a new stake in Tilray Brands in the 3rd quarter valued at $33,000. Clearstead Advisors LLC boosted its holdings in Tilray Brands by 437.3% in the 3rd quarter. Clearstead Advisors LLC now owns 21,625 shares of the company’s stock valued at $37,000 after purchasing an additional 17,600 shares during the period. Finally, Hilton Head Capital Partners LLC bought a new stake in Tilray Brands in the 4th quarter valued at $38,000. 9.35% of the stock is currently owned by institutional investors and hedge funds.

Tilray Brands Stock Performance

Shares of TLRY opened at $5.51 on Monday. The company’s fifty day moving average is $6.20 and its 200-day moving average is $7.91. Tilray Brands has a 12 month low of $3.51 and a 12 month high of $23.20. The firm has a market cap of $642.18 million, a price-to-earnings ratio of -0.40 and a beta of 1.94. The company has a quick ratio of 1.66, a current ratio of 2.79 and a debt-to-equity ratio of 0.19.

Tilray Brands (NASDAQ:TLRY) last announced its quarterly earnings results on Wednesday, April 1st. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.10). Tilray Brands had a negative return on equity of 3.31% and a negative net margin of 156.51%.The business had revenue of $206.73 million for the quarter, compared to analyst estimates of $201.35 million. During the same quarter last year, the company earned ($0.87) EPS. Equities analysts expect that Tilray Brands will post -0.58 EPS for the current fiscal year.

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.